Alternatives to colonoscopy for monitoring colorectal malignancy risk By Sally Robertson.

Neither of these ongoing celebrations endorse or suggest any commercial products, services, or equipment.. Alternatives to colonoscopy for monitoring colorectal malignancy risk By Sally Robertson, medwireNews Reporter Researchers have found there are effective alternatives to colonoscopy screening for managing individuals who have received an initial negative colonoscopy result for colorectal cancer. Rather than continuing further screening with colonoscopy screening every 10 years for such individuals, much less risky and more cost-effective rescreening options may suffice, state Amy Knudsen and co-workers.Beneath the terms of the definitive merger contract between Bristol-Myers Amylin and Squibb, Bristol-Myers Squibb will commence a cash tender offer to get all of the outstanding shares of Amylin’s common stock for $31.00 per share. The agreement also provides for the parties to impact, at the mercy of customary conditions, a merger to end up being completed following a completion of the tender offer which would bring about all shares not really tendered in the tender offer being converted into the right to receive $31.00 per share in cash. The merger agreement contains a provision under which Amylin offers agreed never to solicit any competing gives for the company. Bristol-Myers Squibb will finance the acquisition from its existing cash assets and credit facilities.